US Venture Capital Opens Path to Funding for China Biotech Firms
- Five US startups funded in 2024 to develop drugs from China
- Trend shows potential of China-originated assets, says analyst
This article is for subscribers only.
Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese biotechnology companies have found a new way to cash in on their innovative therapies.
They’re partnering with American venture capitalists to create new, US-based startups built around promising drug compounds, ensuring that they get a healthy payoff should those therapies succeed. The approach is also allowing them to side-step geopolitical tensions that hang over Chinese drug companies’ entry into Western markets.